8St Charles M, Minshall ME, Pandya B J, et al. A cost-ef- fectiveness analysis of pioglitazone plus metformin com- pared with rosiglitazone plus metformin from a third-par- ty payer perspective in the US[J]. Curr Med Res Opin, 2009,25(6):1 343.
9Pinol C, Roze S, Valentine W, et al. Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain[J]. Gac Sanit, 2007,21 (2) : 97.
10Scherbaum WA, Goodall G, Emy-Albrecht KM, et al. Cost-effectiveness of pioglitazone in type 2 diabetes pa- tients with a history of macrovascular disease: a German perspective[J]. Cost EffResour Alloc, 2009,5 (7) : 9.